Genomic Profiling of the Residual Disease of Advanced-stage Ovarian Cancer After Neoadjuvant Chemotherapy

CompletedOBSERVATIONAL
Enrollment

250

Participants

Timeline

Start Date

August 28, 2017

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions
Advanced-stage Ovarian Cancer
Interventions
DRUG

chemotherapy

All of the patients in this study underwent NAC regimens consisting of taxane and platinum combination chemotherapy. After NAC, all of the patients underwent interval debulking surgery. Subsequently, additional cycles of chemotherapy were administered after IDS to complete a total of 6 cycles at the discretion of the treating physician.

Trial Locations (1)

03722

Severance hospital, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT03491033 - Genomic Profiling of the Residual Disease of Advanced-stage Ovarian Cancer After Neoadjuvant Chemotherapy | Biotech Hunter | Biotech Hunter